← Back to Search

Monoclonal Antibodies

tildrakizumab 100 mg for Psoriasis

Phase 4
Waitlist Available
Research Sponsored by Sun Pharma Global FZE
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 4, 8, 12, 16, 28, 40, 52, 64
Awards & highlights

Study Summary

This study is evaluating whether an injection of a drug may help individuals with psoriasis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 4, 8, 12, 16, 28, 40, 52, 64
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 4, 8, 12, 16, 28, 40, 52, 64 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement in Quality of Life Measured by Change From Baseline in Psychological General Well-Being Scale
Secondary outcome measures
Assessment of Patient Happiness With Psoriasis Control Over Time Using Numerical Rating Scale
Assessment of Patient Satisfaction With Treatment Measured by Change From Baseline in Treatment Satisfaction Questionnaire for Medication Over Time
Assessment of Tildrakizumab Overall Satisfaction Over Time Using Numerical Rating Scales
+16 more
Other outcome measures
Treatment-emergent AEs

Side effects data

From 2021 Phase 4 trial • 55 Patients • NCT03718299
13%
Psoriasis
9%
Hypertension
5%
Dermatitis
4%
Nasopharyngitis
4%
Upper respiratory tract infection
4%
Large intestine polyp
4%
Arthralgia
4%
Skin papilloma
4%
Haematuria
4%
Eczema
2%
COVID-19 pneumonia
2%
Transitional cell carcinoma
2%
Ischaemic stroke
2%
IgA nephropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tildrakizumab 100 mg

Trial Design

1Treatment groups
Experimental Treatment
Group I: tildrakizumab 100 mgExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Injections of tildrakizumab
2019
Completed Phase 4
~60

Find a Location

Who is running the clinical trial?

Sun Pharma Global FZELead Sponsor
33 Previous Clinical Trials
10,096 Total Patients Enrolled
6 Trials studying Psoriasis
2,319 Patients Enrolled for Psoriasis
Sun Pharmaceutical Industries LimitedLead Sponsor
64 Previous Clinical Trials
13,456 Total Patients Enrolled
13 Trials studying Psoriasis
2,680 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
2019. "A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03718299.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top